{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:25:50Z","timestamp":1787009150272,"version":"build-2736575974"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To enhance risk stratification in metastatic castrate-resistant prostate cancer (mCRPC), we developed clinical and integrated clinico-genomic prognostic nomograms combining clinical prognostic factors with copy number alteration-based risk scores (RSs) in circulating tumor DNA (ctDNA) and metastatic tissue to predict 1-, 2-, and 3-year overall survival (OS) probabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A clinical prognostic nomogram was developed from publicly accessed Yale University Open Data Access (YODA) data-sciences project (N\u2009=\u20091088 patients). A second publicly available independent dataset (N\u2009=\u200982) with an 11-gene prognostic RS developed concurrently obtained ctDNA and matched metastatic tissue specimens (gains: AR, MYC, COL22A1, PIK3CA, PIK3CB, NOTCH1; losses: TMPRSS2, NCOR1, ZBTB18, TP53, NKX3-1) was used to develop an integrated clinico-genomic survival nomogram. Independent predictors for survival were identified in each dataset using univariate and multivariate Cox proportional hazard. Multivariate regression coefficients with statistical significance (P\u2009&amp;lt;\u2009.05) were used to develop prognostic nomograms to estimate 1-, 2- and 3-year OS probabilities. Nomogram performances were assessed using time-dependent area under curves (t-AUCs). All analyses were conducted in RStudio (v4.1.2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The YODA dataset t-AUCs for the prognostic nomogram for estimating OS at 1, 2, and 3 years were 0.74, 0.70, and 0.74. In the independent second dataset, the integrated clinico-genomic prognostic nomogram was observed to have higher t-AUCs for predicting 3-year mCRPC survival at 0.807 compared with 0.714 using clinical factors alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An integrated clinico-genomic nomogram with ctDNA RSs achieved the highest t-AUC for 3-year survival in mCRPC and may enable precision in identification of poor-prognosis subgroups based on somatic alterations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jncics\/pkag042","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:56:27Z","timestamp":1777377387000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9735-6614","authenticated-orcid":false,"given":"Manish","family":"Kohli","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7019-5494","authenticated-orcid":false,"given":"Anushka","family":"Shankar","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5566-167X","authenticated-orcid":false,"given":"Jennifer","family":"Lloyd","sequence":"additional","affiliation":[{"name":"College of Nursing, University of Utah , Salt Lake City, UT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9364-8572","authenticated-orcid":false,"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, H. Lee Moffitt Cancer Center , Tampa, FL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyue","family":"Huo","sequence":"additional","affiliation":[{"name":"Arizona Center for Telemedicine and Digital Health, Department of Medicine, Division of General Internal Medicine, Geriatrics and Palliative Medicine, College of Medicine - Tucson , University of Arizona, Tucson, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zaki","family":"Fadlullah","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-8369","authenticated-orcid":false,"given":"Aik Choon","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-7441","authenticated-orcid":false,"given":"Joseph","family":"Finkelstein","sequence":"additional","affiliation":[{"name":"Arizona Center for Telemedicine and Digital Health, Department of Medicine, Division of General Internal Medicine, Geriatrics and Palliative Medicine, College of Medicine - Tucson , University of Arizona, Tucson, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026070807270761700_pkag042-B1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026070807270761700_pkag042-B2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026070807270761700_pkag042-B3","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jnci\/djad135","article-title":"Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective","volume":"115","author":"Yoo","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"2026070807270761700_pkag042-B4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026070807270761700_pkag042-B5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.18.01279","article-title":"Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel","volume":"37","author":"Halabi","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026070807270761700_pkag042-B6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/jnci\/djt280","article-title":"Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy","volume":"105","author":"Halabi","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2026070807270761700_pkag042-B7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026070807270761700_pkag042-B8","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.22.02661","article-title":"External validation of a prognostic model of overall survival in men with chemotherapy-naive metastatic castration-resistant prostate cancer","volume":"41","author":"Halabi","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070807270761700_pkag042-B9","article-title":"Prognostic index model for progression-free survival in chemotherapy-naive metastatic castration-resistant prostate cancer treated with abiraterone acetate plus prednisone","author":"Ryan","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2026070807270761700_pkag042-B10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"2026070807270761700_pkag042-B11","doi-asserted-by":"crossref","first-page":"102728","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"key":"2026070807270761700_pkag042-B12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194714","article-title":"Plasma copy number alteration-based prognostic and predictive multi-gene risk score in metastatic castration-resistant prostate cancer","volume":"14","author":"Huang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026070807270761700_pkag042-B13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1200\/PO.20.00424","article-title":"Plasma cell\u2013free DNA profiling of PTEN-PI3K-AKT pathway aberrations in metastatic castration-resistant prostate cancer","volume":"5","author":"Kwan","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2026070807270761700_pkag042-B14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.eururo.2014.07.035","article-title":"Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer","volume":"67","author":"Huang","year":"2015","journal-title":"Eur Urol"},{"key":"2026070807270761700_pkag042-B15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41391-018-0043-z","article-title":"Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients","volume":"21","author":"Kohli","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026070807270761700_pkag042-B16","doi-asserted-by":"crossref","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026070807270761700_pkag042-B17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-016-0556-9","article-title":"miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1","volume":"15","author":"Wang","year":"2016","journal-title":"Mol Cancer"},{"key":"2026070807270761700_pkag042-B18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/annonc\/mdx689","article-title":"A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone","volume":"29","author":"Wang","year":"2018","journal-title":"Ann Oncol"},{"key":"2026070807270761700_pkag042-B19","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"2026070807270761700_pkag042-B20","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/1541-7786.MCR-22-0099","article-title":"Molecular profile changes in patients with castrate-resistant prostate cancer pre- and post-abiraterone\/prednisone treatment","volume":"20","author":"Sicotte","year":"2022","journal-title":"Mol Cancer Res"},{"key":"2026070807270761700_pkag042-B21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070807270761700_pkag042-B22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070807270761700_pkag042-B23","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026070807270761700_pkag042-B24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070807270761700_pkag042-B25","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"2026070807270761700_pkag042-B26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2026070807270761700_pkag042-B27","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2026070807270761700_pkag042-B28","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026070807270761700_pkag042-B29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"2026070807270761700_pkag042-B30","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaf025","article-title":"Multi-gene risk score for prediction of clinical outcomes in treatment-naive metastatic castrate-resistant prostate cancer","volume":"9","author":"Fadlullah","year":"2025","journal-title":"JNCI Cancer Spectr"},{"key":"2026070807270761700_pkag042-B31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.eururo.2025.07.011","article-title":"Pathogenic genomic alterations in circulating tumor DNA predict overall survival in men with metastatic castrate-resistant prostate cancer","volume":"89","author":"Halabi","year":"2026","journal-title":"Eur Urol"},{"key":"2026070807270761700_pkag042-B32","doi-asserted-by":"crossref","first-page":"e2400399","DOI":"10.1200\/PO-24-00399","article-title":"Multigene copy number alteration risk score biomarker-based enrichment study designs in metastatic castrate-resistant prostate cancer","volume":"8","author":"Jo","year":"2024","journal-title":"JCO Precis Oncol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/3\/pkag042\/68457872\/pkag042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/3\/pkag042\/68457872\/pkag042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:27:20Z","timestamp":1783510040000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkag042\/8700385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkag042","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,9]]},"article-number":"pkag042"}}